Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, May 31, 2023 /PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's plenty of anticipation for updates on some of the biggest developments in the world of cancer research. In the past, the event has delivered some major milestones and catalyst events for biotech companies large and small, and this year's lineup is certainly shaping up to deliver more big results. Among the announced lineup of companies that ASCO deemed worthy of an oral presentation features a wide range of players, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Geron Corporation (NASDAQ:GERN), IN8bio, Inc. (NASDAQ:INAB), and Veracyte, Inc. (NASDAQ:VCYT).
Coming off a big win in December 2022 that saw their lead asset pelareorep gain FDA Fast Track Designation for the treatment of advanced/metastatic pancreatic cancer, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is set to once again deliver results on their flagship immunotherapeutic agent. At the 2023 ASCO Annual Meeting, Oncolytics will be making the company's first oral presentation at the event, this time giving an update on its randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer.
"Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "ASCO is widely recognized as one of the world's premier oncology conferences, and we're thrilled that our collaborators at PrECOG will have such a prestigious venue to present the randomized phase 2 BRACELET-1 trial."
The BRACELET Study stands for Breast cAnCEr with the oncolytic reovirus peLareorEp in combination with anti-pd-L1 avelumab and paclitaxel. BRACELET-1 is designed to confirm and expand upon Oncolytics' prior positive clinical results for pelareorep in HR+/HER2- metastatic breast cancer and inform the design of a subsequent registrational study. Previous data from early-stage HR+/HER2- breast cancer patients demonstrated pelareorep's ability to stimulate anti-tumor immunity, remodel tumor microenvironments, and potentially improve patient prognosis by reducing the risk of cancer recurrence.
According to the National Cancer Institute HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases. By 2032, the global breast cancer market is projected to grow at a CAGR of 10.3% to US$85.5 billion.
"Stakeholders across the breast cancer community have demonstrated a keen interest in this readout, which will add to a dataset that already includes statistically significant phase 2 results showing pelareorep's ability to drive a robust overall survival benefit in this indication," added Dr. Coffey in his company's latest Q1 2023 Financial Results announcement, talking about both the core programs of breast and pancreatic cancer. "With these programs both targeting large markets with significant clinical unmet needs and supported by robust clinical proof-of-concept data, we believe confirming their paths towards approval would represent important value-creating events that will substantially de-risk and accelerate pelareorep's development."
In the case of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), the biotech developer, along with its partners, are scheduled to present nine abstracts at ASCO 2023. Among these include an oral presentation from their Phase 2b study of the bispecific antibody zanidatamab in previously treated HER2-amplified billary tract cancer (BTC), as well as another from a Jazz-supported Investigator Sponsored Trial (IST) featuring results from a Phase 1b study evaluating the efficacy of lurbinectedin in combination with doxorubicin in soft-tissue sarcoma (STS), which is intended to serve as a lead-in to a randomized Phase 2 trial in leiomyosarcoma (LMS).
"We are thrilled to present, together with our partner Zymeworks, an oral presentation of pivotal trial results in patients with HER2-positive BTC, an aggressive disease that currently has no FDA-approved HER2-directed treatment options," said Rob Iannone, M.D., M.S.C.E., Executive Vice President, Global Head of Research and Development of Jazz Pharmaceuticals. "The breadth of oncology data being presented by Jazz and our partners reflects our relentless focus on raising the standard of care for some of the most difficult-to-treat cancers."
Data from the pivotal IMerge Phase 3 clinical trial evaluating Geron Corporation's (NASDAQ:GERN) first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), will be delivered through an oral presentation at ASCO 2023. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. The myelodysplastic syndrome treatment market is expected to surpass US$6.6 billion, growing at a 9.3% CAGR from 2023 to 2030.
The Phase 3 portion of the IMerge Phase 2/3 study is a double-blind, 2:1 randomized, placebo-controlled clinical trial to evaluate imetelstat in patients with IPSS Low or Intermediate-1 risk (lower risk) transfusion dependent MDS who were relapsed after, refractory to, or ineligible for, erythropoiesis stimulating agent (ESA) treatment, had not received prior treatment with either a HMA or lenalidomide and were non-del(5q).
Focused on innovative gamma-delta T cell therapies, IN8bio, Inc. (NASDAQ:INAB) was also selected for an oral presentation at ASCO 2023, highlighting new Phase 1 study results evaluating the safety, tolerability and efficacy of INB-200, a potentially promising treatment for newly diagnosed glioblastoma multiforme (GBM). The global GBM treatment market is expected to grow from $2 billion in 2022 to $2.2 billion in 2023, at a CAGR of more than 10%, and onwards to $3.2 billion in 2027.
"We are excited that the Phase I trial of INB-200 in GBM has been selected for an oral presentation at ASCO," said William Ho, CEO and co-founder of IN8bio. "GBM is a highly aggressive and difficult-to-treat brain cancer, where treatment options have remained largely unchanged for almost two decades. The current median progression-free survival with the standard of care for GBM is 6-7 months and overall survival is only 14-16 months. We believe that our unique approach to solid tumor cancers targeting the DNA damage response with our genetically engineered gamma-delta T cells may eliminate more cancer cells and potentially prolong the time to relapse or death."
Lastly, Veracyte, Inc. (NASDAQ:VCYT) has announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at ASCO 2023, including an oral presentation titled FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
FOLFOXIRI is a cancer drug combination that includes folinic acid, fluorouracil (5FU), oxaliplatin and irinotecan. It is a treatment for bowel cancer that has spread to other parts of the body (advanced or metastatic bowel cancer). However, the company is also looking ahead to other abstracts to be showcased at ASCO 2023, including others that use Veracyte technology.
"At Veracyte, we are committed to partnering with the scientific community to uncover new insights that may ultimately help further transform cancer care for patients," said Marc Stapley, CEO of Veracyte. "We particularly look forward to study findings being presented at ASCO that leverage our Decipher GRID database to explore differences in how patients with prostate cancer might respond to particular treatments based on their genomic profiles, and that demonstrate our deep scientific capabilities in immuno-oncology."
The Decipher Genomics Resource for Intelligent Discovery (GRID) database includes more than 100,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its research partners to help advance understanding of prostate and other urologic cancers.
For more information please visit: https://usanewsgroup.com/2022/11/27/market-uncertainty-is-creating-opportunities-that-have-somehow-been-overlooked/
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
U.S. Phone: +1(954)345-0611
Upcoming Life Sciences Events
- September 2023
- Diegem: Pharma-Biotech Product & Company Valuation with Dr. P Frei
- Barcelona: BioSpain 2023
- October 2023
- New York City: BioFuture